IL147547A0 - Blocking immune response to a foreign antigen using an antagonist which binds to cd20 - Google Patents

Blocking immune response to a foreign antigen using an antagonist which binds to cd20

Info

Publication number
IL147547A0
IL147547A0 IL14754700A IL14754700A IL147547A0 IL 147547 A0 IL147547 A0 IL 147547A0 IL 14754700 A IL14754700 A IL 14754700A IL 14754700 A IL14754700 A IL 14754700A IL 147547 A0 IL147547 A0 IL 147547A0
Authority
IL
Israel
Prior art keywords
antagonist
binds
immune response
foreign antigen
blocking immune
Prior art date
Application number
IL14754700A
Other languages
English (en)
Original Assignee
Genentech Inc
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Idec Pharma Corp filed Critical Genentech Inc
Publication of IL147547A0 publication Critical patent/IL147547A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL14754700A 1999-07-12 2000-07-10 Blocking immune response to a foreign antigen using an antagonist which binds to cd20 IL147547A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14440599P 1999-07-12 1999-07-12
PCT/US2000/018776 WO2001003734A1 (en) 1999-07-12 2000-07-10 Blocking immune response to a foreign antigen using an antagonist which binds to cd20

Publications (1)

Publication Number Publication Date
IL147547A0 true IL147547A0 (en) 2002-08-14

Family

ID=22508442

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14754700A IL147547A0 (en) 1999-07-12 2000-07-10 Blocking immune response to a foreign antigen using an antagonist which binds to cd20

Country Status (17)

Country Link
US (1) US20100003252A1 (zh)
EP (1) EP1216056A1 (zh)
JP (1) JP2003528805A (zh)
KR (2) KR20080075044A (zh)
CN (2) CN1373672A (zh)
AU (2) AU778863B2 (zh)
BR (1) BR0013201A (zh)
CA (1) CA2379274A1 (zh)
HK (1) HK1047702A1 (zh)
HU (1) HUP0202238A3 (zh)
IL (1) IL147547A0 (zh)
MX (1) MXPA02000419A (zh)
NO (1) NO20020128L (zh)
NZ (1) NZ516491A (zh)
PL (1) PL201086B1 (zh)
WO (1) WO2001003734A1 (zh)
ZA (1) ZA200200272B (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039550A (ko) 1999-05-07 2008-05-07 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한 자가면역질환의 치료
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002367318B2 (en) * 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003263964C1 (en) * 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
BRPI0316779B8 (pt) 2002-12-16 2023-02-28 Genentech Inc Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida
JP2006522811A (ja) 2003-04-09 2006-10-05 ジェネンテック・インコーポレーテッド ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
WO2005023302A2 (en) * 2003-08-29 2005-03-17 Genentech, Inc. Anti-cd20 therapy of ocular disorders
CN102373214B (zh) 2003-11-05 2014-07-09 罗氏格黎卡特股份公司 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体
KR20060107555A (ko) * 2003-12-19 2006-10-13 제넨테크, 인크. 이식 거부에서 ｃｄ20의 검출
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
KR20070029733A (ko) 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
CA2573192C (en) 2004-08-04 2013-09-10 Applied Molecular Evolution Inc. Variant fc regions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
KR20080047540A (ko) 2005-07-25 2008-05-29 트루비온 파마슈티칼스, 인코포레이티드 Ｃｄ20 특이적 결합 분자의 단회 투여 용도
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
ES2565202T3 (es) 2007-10-16 2016-04-01 Zymogenetics, Inc. Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
SI2132228T1 (sl) 2008-04-11 2011-10-28 Emergent Product Dev Seatle CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
RU2017138926A (ru) 2009-08-11 2019-02-11 Дженентек, Инк. Получение белков в культуральных средах без глутамина
KR102317098B1 (ko) * 2009-11-11 2021-10-25 가니메드 파마슈티칼스 게엠베하 클라우딘 6 특이적 항체
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
EP3909602A1 (en) * 2014-04-25 2021-11-17 University of Florida Research Foundation, Inc. Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
RS60441B1 (sr) 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
EA201890613A1 (ru) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс Полипептиды, связывающие cd3
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
WO2017097723A2 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Treatment method

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
PT752248E (pt) * 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
WO1996031229A1 (en) * 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
DK81095A (da) * 1995-07-11 1997-01-12 Henrik S Thomsen Peroralt MR-kontraststof til lever og øvre tarmkanal
EP0938334A4 (en) * 1996-07-26 2004-12-15 Smithkline Beecham Corp IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
GB2323386A (en) * 1997-03-20 1998-09-23 Procter & Gamble Effervescent detergent granules
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
NZ573838A (en) * 1998-08-11 2011-01-28 Biogen Idec Inc Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6383276B1 (en) * 1999-03-12 2002-05-07 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404365A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceutical Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP1272647B1 (en) * 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
CA2440831C (en) * 2001-04-02 2013-05-28 Genentech, Inc. Combination therapy using cd40 and cd20 ligands
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
BRPI0316779B8 (pt) * 2002-12-16 2023-02-28 Genentech Inc Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida
JP2006522811A (ja) * 2003-04-09 2006-10-05 ジェネンテック・インコーポレーテッド ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
WO2005044998A2 (en) * 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody

Also Published As

Publication number Publication date
PL201086B1 (pl) 2009-03-31
WO2001003734A1 (en) 2001-01-18
HK1047702A1 (zh) 2003-03-07
AU2005201189A1 (en) 2005-04-14
NZ516491A (en) 2004-11-26
HUP0202238A2 (en) 2002-10-28
KR20020027490A (ko) 2002-04-13
PL352758A1 (en) 2003-09-08
US20100003252A1 (en) 2010-01-07
BR0013201A (pt) 2002-04-30
HUP0202238A3 (en) 2004-05-28
NO20020128D0 (no) 2002-01-11
ZA200200272B (en) 2003-03-26
KR20080075044A (ko) 2008-08-13
NO20020128L (no) 2002-02-28
AU2005201189B2 (en) 2008-04-03
AU6082500A (en) 2001-01-30
JP2003528805A (ja) 2003-09-30
EP1216056A1 (en) 2002-06-26
AU778863B2 (en) 2004-12-23
CA2379274A1 (en) 2001-01-18
CN1373672A (zh) 2002-10-09
CN101264324A (zh) 2008-09-17
MXPA02000419A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
IL147547A0 (en) Blocking immune response to a foreign antigen using an antagonist which binds to cd20
IL155340A0 (en) HUMANIZED ANTI LYMPHOTOXIN-beta-RECEPTOR ANTIBODIES
IL156030A0 (en) Humanized antibodies
HUP0204074A3 (en) Humanized antibodies that sequester abetha peptide
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
IL229857A0 (en) 1rp7b mature polypeptide binding antibody
EP1633785A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
IL156304A0 (en) Cxcr3 antagonists
EP1117438A4 (en) ANTAGONIST ANTIBODIES OF TIE2
AU2003264009A8 (en) Humanized rabbit antibodies
IL166244A0 (en) Super humanized antibodies
EP1151012A4 (en) ANTAGONIST ANTIBODIES OF RHAMM
EP1567555A4 (en) HUMANIZED ANTIBODIES AGAINST CHEMOTOXIC MONOCYTE PROTEINS
EP1178829A4 (en) HUMAN MONOCLONAL ANTIBODY
HU9800613D0 (en) Humanized anti-human fas antibody
EP1272205A4 (en) FACTOR-2 ANTIBODIES OF SIALOADHESINE
EP1484398A4 (en) ANTIGEN OF HUMAN GLIOMA OF TESTICULAR ORIGIN
ITPD20000192A0 (it) Anticorpi policlonali
GB0008160D0 (en) Monoclonal antibodies
GB0003359D0 (en) Monoclonal antibodies
GB0030139D0 (en) Monoclonal antibody
GB0029846D0 (en) Monoclonal antibody
GB0016824D0 (en) Human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies
GB0020794D0 (en) Humanised antibodies